As reported in breast cancer, where trastuzumab has been demonstrated to have significant therapeutic effect in patients with strong (i.e., score 3+ by IHC) or FISH-positive disease (Slamon et al, 2001, 2006; Baselga et al, 2005), USC patients refractory to standard treatment modalities may potentially benefit from Her2/neu-targeted therapy (Villella et al, 2006; Santin et al, 2008). Here, ERBB2 is linked to breast cancer.